Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.

Authors

Tessa Knox
Eva Sahakian
Debarati Banik
Melissa Hadley
Erica Palmer
Satish Noonepalle
Jennifer Kim
John Powers
Maria Gracia-Hernandez
Vasco Oliveira
Fengdong Cheng
Jie Chen
Cyril Barinka
Javier Pinilla-Ibarz
Norman H Lee
Alan Kozikowski
Alejandro Villagra, George Washington University

Document Type

Journal Article

Publication Date

4-16-2019

Journal

Sci Rep

Volume

9

Issue

1

DOI

10.1038/s41598-019-42237-3

Comments

This is an open access PubMed Central article.

APA Citation

Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., Cheng, F., Chen, J., Barinka, C., Pinilla-Ibarz, J., Lee, N., Kozikowski, A., & Villagra, A. (2019). Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.. Sci Rep, 9 (1). http://dx.doi.org/10.1038/s41598-019-42237-3

Peer Reviewed

1

Open Access

1